India’s Pharmaceutical Revolution: A $450 Billion Opportunity
For global suppliers and equipment manufacturers, this marks a once-in-a-generation opportunity to become part of India’s evolving pharmaceutical ecosystem.
For global suppliers and equipment manufacturers, this marks a once-in-a-generation opportunity to become part of India’s evolving pharmaceutical ecosystem.
India’s pharmaceutical sector is on the brink of a transformation that could redefine global healthcare manufacturing. Valued at around US $55 billion in 2025, the industry is projected to touch US $120–130billion by 2030 and an ambitious US $450 billion by 2047 under the India@100vision.
This momentum isn’t just about volume growth. It signals a deep structural shift from low-cost generics toward complex therapies, biologics, and high-value specialty drugs.
For global suppliers and equipment manufacturers, this marks a once-in-a-generation opportunity to become part of India’s evolving pharmaceutical ecosystem.
India accounts for 20% of global generic drug supply and remains a cornerstone of affordable vaccines worldwide, producing 55–60% ofUNICEF’s vaccines, 99% of WHO’s DPT vaccine demand, and 45% of measles vaccines. With over 2,000 WHO-GMP-approved facilities and the largest number ofUSFDA-compliant plants outside the U.S., the country has built unmatched manufacturing credibility.
Domestic pharmaceutical sales are also expanding strongly.According to a CareEdge(CARE Ratings) report, India’s domestic market grew by 9% year-on-year in FY 2023-24, supported by rising demand across both acute and chronic therapies, new product launches and price revisions permitted by theNPPA. The domestic pharma sales are projected to increase from US$ 25billion in 2024 to US$ 50 billion by 2030, with over 40% of this growth coming from Tier II and Tier III cities. These trends underscore a large, under-penetrated domestic market, particularly for branded generics, chronic care therapies, and nutraceuticals, presenting a significant opportunity for equipment suppliers.
India’s traditional strength in low-cost generics is now giving way to higher-margin, innovation-driven segments. This evolution brings fresh equipment demands and deeper technical sophistication across the value chain.
API Self-Reliance
Reducing dependence on imported Active Pharmaceutical Ingredients (APIs) isa national priority. Government schemes now support domestic production of key starting materials, creating opportunities for manufacturers of reactors, crystallisers, filtration systems and solvent-recovery units.
Biologics and Biosimilars
India’s biotechnology sector has grown 13-fold in a decade, from US $10billion in 2014 to US $130 billion in 2024, and could touch US $300 billion by2030. Demand for sterile, high-precision biomanufacturing infrastructure like bioreactors, chromatography systems and aseptic fill-finish lines is accelerating.
Contract Research & Manufacturing (CRDMO) Services
India’s CRDMO industry is expected to double to ₹1.2 lakh crore (US $14billion) by 2028, driven by biologics outsourcing and specialty drug development. This shift expands the market for flexible, modular production systems, analytical instrumentation and quality-control equipment.
Chronic Disease Focus
Chronic therapies (cardiac, diabetic, respiratory) now make up 38% of the domestic market. Their production requires equipment built for continuous processing, precise dosing, and enhanced stability testing, signalling a move toward technology-intensive plants.
The pharmaceutical and medical device sectors attracted₹11,888 crore in FDI between April–December FY 2024-25, along with ₹7,246 crorein additional brownfield proposals taking total inflows to over ₹19,000 crore.
Flagship infrastructure projects highlight the shift toward self-reliance:
According to the Economic Survey 2023–24, India’s bulk drug exports reached ₹ 39,632 crore, surpassing imports of ₹37,722 crore—marking a shift toward self-reliance in key inputs for the first time in recent years.
The proposed U.S. Biosecure Act, which restricts procurement from certain Chinese biotech firms, has accelerated a re-evaluation of global supply chains. For India, this presents a clear strategic window.
India’s CDMO (Contract Development and ManufacturingOrganisation) ecosystem, long rooted in APIs and generics, is now being positioned for biologics, sterile injectables and higher-value work.
According to recent reports, India’s CDMO market is expected to grow from about US $7billion to US $14 billion by 2028 (capturing ~4-5% of the globalCDMO market).
While China currently holds about 8% of the global CDMO market, India’s share is just 2.7% but growing fast. Industry analysts estimate India’s CDMO market, valued at ₹18,800 crore in 2024, could double to ₹37,200 crore by 2029 at a 14.7% CAGR, outpacing global averages.
These shifts reflect global pharma firms diversifying away from China, favouring India for cost, compliance and scale. For equipment suppliers, the implication is clear: plants built for CDMO/outsourcing demand more advanced, flexible, modular equipment and servicing.
This geopolitical realignment, combined with India’s expanding biologics and biosimilars capacity, positions the country as a credible partner in resilient, multi-country pharmaceutical supply chains.
Multinational and Indian players like GSK, Sanofi, Cipla, and Dr. Reddy’s are deploying Industry 4.0 technologies to enhance efficiency and compliance. Equipment makers offering smart, digital-ready, and regulatory-integrated systems will capture the lion’s share of new investments.
Cipla and Dr. Reddy’s Laboratories, two leading Indian firms, have invested heavily in automation, digital manufacturing and export-compliant facilities. They are upgrading sterile fill-finish lines, real-time quality monitoring systems, and flexible packs to serve global markets. This creates demand for high-precision equipment, clean-room installations, and digital quality-control systems.
Sanofi, a global MNC, has announced expansions in India aimed at both domestic supply and export from India. Their India manufacturing units are being modernised to comply with global audit standards and are increasingly sourcing equipment locally – offering opportunity for suppliers who provide validated systems and service support.
For equipment manufacturers targeting import-substitution, MSME-oriented local plants upgrading their manufacturing are a critical segment. These plants often require equipment adapted to Indian operating conditions, including modular capacity, cost-sensitive design, local after-sales support, and spares.Suppliers who engage with these user-plants will capture the most durable value.
India’s pharma production clusters are geographically concentrated, creating ecosystem advantages.
For equipment suppliers, presence in these clusters provides early-stage engagement, local servicing networks, and access to anchor clients shaping long-term demand.
1. Localisation and Partnership
Indian buyers value proximity, service, and technical collaboration. Establishing local assembly, after-sales service, and joint-development models creates long-term relationships and reduces import-barrier frictions.
2. Lifecycle Solutions
Beyond installation, offering qualification, training, preventive maintenance, spare parts, and upgrades generates recurring revenue and enhances customer stickiness over the equipment lifecycle.
3. Modular & Scalable Design
Indian manufacturers often scale incrementally. Modular platforms that can expand without major infrastructure changes align perfectly with this growth pattern.
4. Regulatory Alignment
Suppliers who integrate compliance support like validation documentation, quality training, audit readiness, etc stand out in a market pushing to close the gap with global inspection standards.
5. Financing Flexibility
Capital-intensive pharma manufacturing often limits mid-sized firms from adopting next-generation technology. Structured financing options, such asOEM-led deferred payment plans, equipment buybacks, or long-term service-linked agreements, can ease cash flow pressures while maintaining compliance integrity and ensuring full equipment traceability.
Expanding into India’s pharma manufacturing ecosystem requires regulatory understanding, local insight and execution strength besides world-class technology.
With MindStep you get:
Market & Opportunity Assessment – A deep dive into your current capabilities and India’s sector potential. Understand where your technology fits and what capabilities to strengthen.
Build a Go-to-Market Strategy – Tailored plans aligned with your global vision and India’s specific policy and customer context.
Execution Support – On-ground guidance, leadership coaching, and regular reviews to ensure strategy translates into measurable results.
Localisation – Assistance in building supply chains, hiring skilled talent, and adapting operations to India’s unique market andregulatory environment.
India’s pharmaceutical sector is at a defining moment. The convergence of policy incentives, domestic demand, global supply-chain shifts and biotech expansion is unlocking vast potential across the value chain.
For global suppliers, the question is no longer whether to engage but how soon to position for advantage. Those who localise, collaborate and innovate for India’s specific needs will shape the next phase of global pharma manufacturing.
India is redefining the architecture of global pharmaceutical supply. Equipment manufacturers that align now will grow alongside it.
B 203, Gala Quest, Paranjpe Road no. 1, Vile Parle East, Mumbai 400057, India.
sales@mindstepconsultancy.com
+91 842 406 3466
Copyright © 2025 MindStep Consultancy